Amanda Kile, DO
Endocrinology, Diabetes & Metabolism · Seymour, INNPI 1255726295
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 473 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations.
Across 473 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$850
- Dexcom, Inc.$774
- Corcept Therapeutics$490
- Medtronic$469
- AstraZeneca$384
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,58999%
- Education$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 86 | $1,246 |
| Lilly USA, LLC | 56 | $850 |
| Dexcom, Inc. | 72 | $774 |
| Corcept Therapeutics | 24 | $490 |
| Medtronic(2 entities) | 18 | $469 |
| AstraZeneca(2 entities) | 22 | $384 |
| Novartis | 19 | $339 |
| Radius Health, Inc. | 20 | $323 |
| Xeris Pharmaceuticals, Inc. | 18 | $306 |
| Amgen(2 entities) | 13 | $237 |
| Insulet Corporation | 11 | $221 |
| Boehringer Ingelheim | 13 | $209 |
| Bayer | 14 | $207 |
| AbbVie | 12 | $199 |
| Mannkind Corporation | 8 | $189 |
| Abbott | 11 | $158 |
| Recordati_rare_diseases_inc. | 8 | $152 |
| Sanofi-aventis U.S. LLC | 7 | $129 |
| Lifescan, Inc. | 8 | $111 |
| Amarin Pharma, Inc. | 6 | $107 |
| Cequr Corporation | 2 | $101 |
| IBSA Pharma Inc. | 3 | $49 |
| Sequel Med Tech, LLC | 2 | $48 |
| Kyowa Kirin, Inc. | 2 | $47 |
| Ascendis Pharma Endocrinology Inc | 2 | $42 |
| Tandem Diabetes Care, Inc. | 2 | $34 |
| Zealand Pharma US, Inc. | 2 | $33 |
| GSK | 2 | $30 |
| Halozyme Inc | 2 | $28 |
| BD | 1 | $25 |
| Averitas Pharma Inc. | 1 | $23 |
| EUSA Pharma (US) LLC | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Pfizer | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
How this compares
$7,656 in reported general payments places this provider in the 75th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 253 | $268,551 |
| OzempicSemaglutide | 138 | $145,387 |
| TymlosAbaloparatide | 38 | $121,492 |
| TrulicityDulaglutide | 87 | $99,875 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 116 | $99,283 |
| FarxigaDapagliflozin Propanediol | 105 | $98,526 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 39 | $96,665 |
| JardianceEmpagliflozin | 112 | $94,602 |
| Tresiba Flextouch U-100Insulin Degludec | 96 | $58,561 |
| Humalog Kwikpen U-200Insulin Lispro | 24 | $39,922 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $32,711 |
| Bydureon BciseExenatide Microspheres | 19 | $27,613 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 89 | $22,354 |
| Gvoke Hypopen 2-PackGlucagon | 34 | $21,034 |
| Novolog FlexpenInsulin Aspart | 67 | $18,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $850 | $368,426340 claims |
| Novo NordiskOzempic | $1,246 | $145,387138 claims |
| Radius Health, Inc.Tymlos | $323 | $121,49238 claims |
| Boehringer IngelheimJardiance, Tradjenta | $209 | $100,133124 claims |
| AstraZenecaFarxiga | $384 | $98,526105 claims |
| IBSA Pharma Inc.Tirosint | $49 | $4,31420 claims |
| AbbVieSynthroid | $199 | $3,30647 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Seymour
- Emily VeenemanSeymour$583K
- Kristen GilbertSeymour$10K
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Nihad MuhrezMerrillville$271K
- Hisham AllababidiIndianapolis$195K
- Neha GavinFishers$149K
- Edward RicoTerre Haute$135K
- Dona GrayLafayette$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.